Breaking News
July 17, 2018 - Advanced MRI technique predicts risk of disease progression in MS
July 17, 2018 - Health Tip: Microwave Safely – Drugs.com MedNews
July 17, 2018 - New target for treating heart failure identified
July 17, 2018 - Biodesign fellows simplify heart rhythm monitoring
July 17, 2018 - Study reveals new risk genes for allergic rhinitis
July 17, 2018 - Community college education can increase physician diversity and access to primary care
July 17, 2018 - Inflection Biosciences’ dual mechanism inhibitor shows promise as treatment for CLL
July 17, 2018 - Researchers uncover how cells invite corrupted proteins inside
July 17, 2018 - Studies show HORIBA’s new hematology analyzer improves POCT and care of oncology patients
July 17, 2018 - New website aims to make yoga safer for everyone
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Homogenous BTK occupancy assay used in tirabrutinib clinical studies
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
July 17, 2018 - Improved methods to measure enterococci concentrations in recreational water
July 17, 2018 - White adolescent boys experiencing early puberty have high risk for substance use
July 17, 2018 - Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 17, 2018 - Roots of leukemia reveal possibility of predicting people at risk
July 17, 2018 - Summer med program embraces low-income students’ potential
July 17, 2018 - New research lays foundation to create standards for RNA sequencing
July 17, 2018 - CRISPR/Cas9 gene editing can cause greater genetic damage than previously thought
July 17, 2018 - Democrats rally against threats to the ACA to block Trump’s Supreme Court nominee
July 17, 2018 - Staggering prices slow insurers’ coverage of CAR-T cancer therapy
July 17, 2018 - How proteins involved in neurodegeneration enter cells
July 17, 2018 - New super-resolution ‘nanoscope’ provides insight into progression of Alzheimer’s disease
July 17, 2018 - FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
July 17, 2018 - Uncovering the evolutionary history of IBD-associated colorectal cancer
July 17, 2018 - Is nutrition research dependable? Stanford’s John Ioannidis weighs in
July 17, 2018 - New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions
July 17, 2018 - Plant-based products fail to have positive impact on blood pressure during clinical studies
July 17, 2018 - Electronic system to speed up facial pain diagnosis may improve quality of life and save money
July 17, 2018 - Study delves into the role played by Protein Kinase C in synaptic plasticity
July 17, 2018 - Women Often Unaware of Their Hospital’s Religious Affiliation
July 17, 2018 - New AASM guideline recommends use of actigraphy for sleep disorders
July 17, 2018 - CRISPR editing reduces repetitive behavior in mice with a form of autism
July 17, 2018 - Scientists use magnets to detect cancer
July 17, 2018 - Microfluidic chip to detect sepsis proves successful in clinical study
July 17, 2018 - Research provides better understanding of mechanisms underlying memory storage
July 17, 2018 - A Multi-Modal Approach for the Early Detection of Breast Cancer
July 17, 2018 - Mailing colorectal cancer tests to patients increases screening rates, report researchers
July 17, 2018 - Scientists find possible sources of medicinal and antimicrobial drugs
July 17, 2018 - Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer
July 17, 2018 - Efficient communication between hospitals improves patient safety and reduces mortality
July 17, 2018 - Study highlights potential of fetal gene therapy to prevent lethal neurodegenerative disease
July 17, 2018 - For Americans, in Science They Trust
July 17, 2018 - Combating HIV/AIDS | NIH MedlinePlus the Magazine
July 17, 2018 - Study shows minorities widely underrepresented in autism diagnoses
July 17, 2018 - Multigene testing replacing BRCA tests for breast cancer risk | News Center
July 17, 2018 - Pre-clinical pilot study shows promising results of ‘concussion pill’
July 17, 2018 - Researchers reduce size of tumors in mice by artificially activating the brain’s reward system
July 17, 2018 - New study documents symptoms of people before they acquire multiple sclerosis
July 17, 2018 - Researchers discover why CRISPR gene editing sometimes fails
July 17, 2018 - New finding may hold key to better understand the complexities of neurological disorders
July 17, 2018 - The Current issue of “The view from here” is concerned with Novel Targets.
July 17, 2018 - Fighting the Flu with a Universal Vaccine
July 17, 2018 - Key social reward circuit in the brain impaired in kids with autism | News Center
July 17, 2018 - Insight into causes, types and treatment of aphasia
July 16, 2018 - Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
July 16, 2018 - NSAIDs shown to have causal role in cardiovascular risk of patients with osteoarthritis
July 16, 2018 - PET scan tracer predicts success of cancer ‘vaccine’ | News Center
July 16, 2018 - Parents struggle with what to do when their child has headache, shows study
July 16, 2018 - Outrageous or overblown? HHS announces another round of ACA navigator funding cuts
July 16, 2018 - Weight loss surgery may impact individual’s risk of developing cancer, shows study
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
July 16, 2018 - Can nanotechnology help treat Alzheimer’s?
July 16, 2018 - Researchers identify protein essential for making stem cells | News Center
July 16, 2018 - Severe childhood infections linked with lower school achievement in adolescence
July 16, 2018 - Radiologist discusses causes, treatments of varicose veins
July 16, 2018 - Researchers develop nanostructured surface to accelerate wound healing after dental implants
July 16, 2018 - New non-invasive procedure to reposition kidney stones could benefit astronauts
July 16, 2018 - Attending Surgeon Influences Genetic Testing in Breast Cancer
Shorter Preventive TB Tx Effective for HIV+ Patients

Shorter Preventive TB Tx Effective for HIV+ Patients

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals, a 1-month course of isoniazid/rifapentine, was comparable to the lengthier usual-care regimen for rates of TB and death.
  • Note that serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant.

BOSTON — A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals was comparable to the lengthier usual-care regimen for rates of TB and death, a late-breaking phase III randomized trial presented here found.

A 1-month course of isoniazid/rifapentine, an antibiotic regimen for TB prevention, was found to be safe and effective when compared with the usual 9-month course of isoniazid alone in people with HIV infection, reported Richard E. Chaisson, MD, of Johns Hopkins University in Baltimore.

Constance Benson, MD, of the University of California San Diego, who moderated the press conference at the Conference on Retroviruses and Opportunistic Infections (CROI), but was not involved in the research, characterized these findings as having “the potential to immediately change clinical practice.”

In a separate statement released by the National Institutes of Health, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, agreed, saying that these results “offer people living with HIV who are at risk of developing active [TB] an additional, shorter-duration prevention option that is safe, effective and more convenient.”

At the press conference, Chaisson said that while prevention of TB with isoniazid is effective, “uptake has been appallingly bad.” He added that the longer the course of the therapy is, the more people stop taking it, and described “a sense of futility” among clinicians about this problem.

A shorter, 4-week course of rifapentine and isoniazid had shown promise in animal studies, the authors said, so they hypothesized it would be non-inferior to the usual 9-month standard of care. “The bottom line is,” Chaisson added, “it was.”

Participants were eligible if they were HIV-infected individuals age 13 or older with no evidence of active TB, who had either a positive TB skin or blood test (Interferon Gamma Release Assay, or IGRA) or lived in an area with a high burden of TB (prevalence ≥60/100,000 population). They were stratified by CD4-positive cell count and antiretroviral therapy (ART) use at entry.

After randomization, patients received either 300-mg isoniazid plus 450- to 600-mg rifapentine once daily for 4 weeks or 300-mg isoniazid daily for 9 months. They were then followed for 3 years after the last participant was enrolled. ART with efavirenz or nevirapine was permitted.

Overall, 1,488 patients in the intervention group and 1,498 patients in the control group were included in the analysis. More than half were women, two-thirds were black and median body mass index was 23.5. Median CD4 count was 470 cells/mm³, and half were on ART at entry. Around 20% had a positive TB skin or blood test. The primary endpoint was the incidence rate ratio of active TB, TB death, or death due to an unknown cause, and the non-inferiority margin was 1.25 per 100 person-years.

The intervention group had an incidence of 0.65 per 100 person-years and the control group had an incidence of 0.67 per 100 person-years (IRR difference 0.023, 95% CI -0.30 to 0.35).

Rates of the primary outcome were higher for patients not on ART at entry and those with a positive TB skin or blood test, but no difference between treatments was noted, the authors said. In addition, rates were higher in the intervention group among those with baseline CD4 counts of ≤250 mm3, but the difference was not statistically significant.

Serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant. The authors noted that safety was “similar” in both arms, with more hematologic toxicity in the intervention group and more liver and neurotoxicity in the control group.

Chaisson said that the study was unlikely to be replicated, but characterized this as a “large enough, clear enough answer that it can be acted upon.” He added that he hoped this therapy would be studied in people without HIV.

The next steps would be incorporating these findings into guidelines. Chaisson said that he shared his results with the World Health Organization and encouraged them to incorporate this into new guidelines, perhaps as an amendment, “as quickly as possible.”

Chaisson disclosed support from Otsuka.

Sanofi supplied study medications for this trial.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-09-03T00:00:00-0400

last updated

Tagged with:

About author

Related Articles